Monayer Antoinette, Minha Sa'ar, Maymon Shiri L, Pereg David, Kalmanovich Eran, Moravsky Gil, Grupper Avishay, Marcus Gil
Department of Cardiology, Shamir Medical Center, Zeriffin, Israel.
Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Int J Cardiol Heart Vasc. 2024 May 20;53:101431. doi: 10.1016/j.ijcha.2024.101431. eCollection 2024 Aug.
Statin therapy is well-established for treating hyperlipidemia and ischemic heart disease (IHD), but its role in Acute Decompensated Heart Failure (ADHF) remains less clear. Despite varying clinical guidelines, the actual utilization and impact of statin therapy initiation in patients with ADHF with an independent indication for statin therapy have not been thoroughly explored.
We conducted a retrospective observational study on 5978 patients admitted with ADHF between January 1st, 2007, and December 31st, 2017. Patients were grouped based on their statin therapy status at admission and discharge. We performed multivariable analyses to identify independent predictors of short-term, intermediate-term, and long-term mortality. A sensitivity analysis was also conducted on patients with an independent indication for statin therapy but who were not on statins at admission.
Of the total patient cohort, 73.9% had an indication for statin therapy. However, only 38.2% were treated with statins at admission, and 56.1% were discharged with a statin prescription. Patients discharged with statins were younger, predominantly male, and had a higher prevalence of IHD and other comorbidities. Statin therapy at discharge was an independent negative predictor of 5-year all-cause mortality (hazard ratio 0.80, 95% confidence interval 0.76-0.85). The sensitivity analysis confirmed these findings, demonstrating higher mortality rates in patients not initiated on statins during admission.
The study highlights significant underutilization of statin therapy among patients admitted with ADHF, even when there's an independent indication for such treatment. Importantly, initiation of statin therapy during hospital admission was independently associated with improved long-term survival.
他汀类药物治疗在高脂血症和缺血性心脏病(IHD)的治疗中已得到充分确立,但其在急性失代偿性心力衰竭(ADHF)中的作用仍不太明确。尽管临床指南各不相同,但对于有他汀类药物治疗独立指征的ADHF患者,他汀类药物治疗起始的实际应用情况和影响尚未得到充分探讨。
我们对2007年1月1日至2017年12月31日期间收治的5978例ADHF患者进行了一项回顾性观察研究。患者根据入院时和出院时的他汀类药物治疗状态进行分组。我们进行了多变量分析,以确定短期、中期和长期死亡率的独立预测因素。还对有他汀类药物治疗独立指征但入院时未服用他汀类药物的患者进行了敏感性分析。
在整个患者队列中,73.9%有他汀类药物治疗指征。然而,入院时仅38.2%接受了他汀类药物治疗,56.1%出院时开具了他汀类药物处方。出院时服用他汀类药物的患者更年轻,以男性为主,IHD和其他合并症的患病率更高。出院时的他汀类药物治疗是5年全因死亡率的独立负性预测因素(风险比0.80,95%置信区间0.76-0.85)。敏感性分析证实了这些发现,表明入院时未开始服用他汀类药物的患者死亡率更高。
该研究突出了ADHF患者中他汀类药物治疗的显著未充分利用情况,即使存在这种治疗的独立指征。重要的是,入院期间开始他汀类药物治疗与改善长期生存率独立相关。